Author of

• 32148

  +

  EP1.14 - Targeted Therapy (ID 204)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32165

    +

    EP1.14-13 - EGFR Mutation in Lung Adenocarcinoma: Real World Study from a Single Institute (ID 2537)

    08:00 - 18:00  |  Author(s): Wenyuan Shang
    • Abstract

    Background
    

    To investigate the EGFR mutation in lung adenocarcinoma of real world.

    Method
    

    Patients diagnosed lung adenocarcinoma and performed EGFR mutation analysis in Liaoning Cancer Hospital & Institute from June 2014 to April 2018 were collected retrospectively. Gender, age, EGFR mutation status of patients were analyzed.

    Result
    

    There were 779 patients included in the study. Of all patients, 365 were male, 414 were female, median age was 60 years-old (range 29-80). EGFR mutation analysis showed that there were 417 mutation cases, 362 were negative, the overall mutation rate was 53.5%. For male patients, the mutation rate was 37.0% (135/365), and 68.1% for female patients (282/414). Seven hundred and sixty-one patients had one EGFR mutation type, 17 had two types, and 1 had three types. The most common type of EGFR mutation was Exon 21 L858R (204/436, 46.8%), and the second common was Exon 19 deletion (175/436, 40.4%), other mutation types were significantly less, including Exon 20 insertion (20/436, 4.6%), Exon 18 G719X (19/436, 4.4%), Exon 20 S768I (10/436, 2.3%), Exon 21 L861Q (5/436, 1.1%). Primary resistance of T790M mutation were found in 3 patients (0.7%), however, all the 3 cases had two types of mutations besides T790M mutation (2 Exon 19 deletion and 1 Exon 21 L858R).

    Conclusion
    

    The overall EGFR mutation rate was over 50% in our institution, and higher in female patients, about 70%. The most common mutations were Exon 21 L858R and Exon 19 deletion, and other mutation types were rare. Finally, T790M mutation often combined with the other type of EGFR mutations.